natgillin/translations-raw huggingface dataset:
The antibody or antigen-binding fragment for the use according to claim 6, wherein the use is for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis or ankylosing spondylitis. 
Protutijelo ili antigen-vezujući fragment u skladu s patentnim zahtjevom 16, pri čemu je uporaba tretiranje psorijaze, upalne bolesti crijeva, psorijatičnog artrirtisa, multiple skleroze, reumatoidnog artritisa, Chronove bolesti, ulceroznog kolitisa ili ankilozantnog spondilitisa.
A pharmaceutical composition comprising an antibody or antigen-binding fragment according to any one of claims 1 to 21 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća protutijelo ili antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 14 i farmaceutski prihvatljivi nosač.
A method of selecting and amplifying polynucleotides on a solid support, comprising: 
Metoda za odabir i umnožavanje polinukleotida na čvrstoj podlozi, obuhvaća:
sequencing a first strand of the solid-phase amplification product of step f) to obtain at least part of the nucleotide sequence of the template polynucleotide. 
sekvenciranje prvog lanca produkta umnožavanja na čvrstoj fazi iz koraka f) zbog dobivanja barem dijela slijeda nukleotida polinukleotida kalupa.
The method of claim 2, wherein said solid-phase amplification products comprise a binding site for a universal sequencing primer. 
Metoda iz patentnog zahtjeva 2, pri čemu produkti umnožavanja na čvrstoj fazi obuhvaćaju vezno mjesto za univerzalnu početnicu za sekvenciranje.
The method of claim 1, wherein the capture oligonucleotides comprise at least 10 different capture sequences. 
Metoda iz patentnog zahtjeva 1, pri čemu vezni oligonukleotidi sadrže najmanje 10 različitih veznih slijedova.
The method of claim 5, wherein reversible blocking is by a chemical species attached to a 3' end of the amplification oligonucleotides. 
Metoda iz patentnog zahtjeva 5, pri čemu je reverzibilno blokiranje pomoću kemijskih vrsta pričvršćenih na 3' kraju oligonukleotida za umnožavanje.
The method of claim 5, wherein the chemical species is a phosphate group. 
Metoda iz patentnog zahtjeva 6, pri čemu je kemijska vrsta fosfatna grupa.
The method of claim 1, wherein the amplification is isothermal. 
Metoda iz patentnog zahtjeva 1, pri čemu je umnožavanje izotermalno.
The method of claim 1, wherein one end of the template polynucleotides comprises an adapter sequence. 
Metoda iz patentnog zahtjeva 1, pri čemu dio produljenih produkata komplementaran s neproduljenim oligonukleotidima za umnožavanje obuhvaća adapterski slijed.
The method of claim 9, wherein the template polynucleotides in the nucleic acid sample comprise different sequences and the adapter sequence is the same for each template polynucleotides. 
Metoda iz patentnog zahtjeva 9, pri čemu polinukleotidi kalupa u uzorku nukleinske kiseline obuhvaćaju različite sljedove i adapterski slijed je isti za svaki polinukleotid kalupa.
The inhibitor of the CD95 signalling pathway for the use according to claim 1, wherein the inhibitor is a compound which improves the growth of erythroid progenitors. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 1, pri čemu je inhibitor tvar koja poboljšava rast eritroidnih progenitora.
The inhibitor of the CD95 signalling pathway for the use according to claim 1 or 2, wherein the inhibitor is an CD95 receptor molecule or a CD95 ligand- binding portion thereof and/or CD95-ligand inhibitor. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je inhibitor molekula CD95 receptora ili njegov CD95 ligand-vezujući dio i/ili inhibitor CD95-liganda.
The inhibitor of the CD95 signalling pathway for the use according to claim 1 or 2, wherein the inhibitor is a fusion protein that binds to a CD95L. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je inhibitor fuzijski protein koji veže CD95L.
The inhibitor of the CD95 signalling pathway for the use according to claim 5, wherein the fusion protein comprises an extracellular domain or a functional fragment thereof and a human Fc domain or a functional fragment thereof. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 5, pri čemu fuzijski protein sadrži vanstaničnu domenu ili njen funkcionalni fragment i ljudsku Fc domenu ili njen funkcionalni fragment.
The inhibitor of the CD95 signalling pathway for the use according to any of claims 1 to 10, which is provided as pharmaceutical composition comprising pharmaceutically acceptable carriers, diluents and/or adjuvants. 
Inhibitor CD95 signalnog puta za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 10, koji je omogućen kao farmaceutski sastav koji sadrži farmaceutski prihvatljive nosače, diluente i/ili adjuvanse.
The inhibitor of the CD95 signalling pathway for the use according to any of claims 1 to 11, which is provided as pharmaceutical composition comprising at least one further active ingredient such as an erythropoiesis stimulating agent and/or apoptosis inhibiting agent. 
Inhibitor CD95 signalnog puta za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 11, koji je omogućen kao farmaceutski sastav koji sadrži barem jedan dodatni aktivni sastojak kao što je agens za stimulaciju eritropoeze i/ili agens za blokiranje apoptoze.
The pharmaceutical composition according to any one of claims 1 to 3, wherein the inhibitor is an CD95 receptor molecule or a CD95 ligand-binding portion thereof and/or CD95-ligand inhibitor. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je inhibitor molekula CD95 receptora ili njegov CD95 ligand-vezujući dio i/ili inhibitor CD95-liganda.
The pharmaceutical composition according to any one of claims 1 to 3, wherein the inhibitor is a fusion protein that binds to a CD95L. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je inhibitor fuzijski protein koji veže CD95L.
or a salt or hydrate thereof. 
ili njegova sol ili hidrat.
a diluent or filler comprising a combination of microcrystalline cellulose and lactose; 
otapalo ili sredstvo za punjenje koje sadrži kombinaciju mikrokristala celuloze i laktoze;
at least one disintegrant comprising croscarmellose sodium; 
najmanje jedno sredstvo za dezintegraciju koje sadrži kroskarmeloz natrij;
at least one binder comprising hydroxypropyl cellulose; and 
najmanje jedno sredstvo za vezivanje koje sadrži hidroksipropil celulozu; i
the diluent or filler is present in an amount within the range of from 10% to 95% by weight; the disintegrant is present in an amount within the range of from 0.1% to 20% by weight; 
otapalo ili sredstvo za punjenje zastupljeno u količini u rasponu od 10% do 95% po masi; sredstvo za dezintegraciju zastupljeno u količini u rasponu 0.1% do 20% po masi;
The pharmaceutical composition of claim 1 wherein the diluent or filler is present in an amount within the range of from 30% to 50% by weight. 
Farmaceutski sastav prema patentnom zahtjevu 1 gdje je otapalo ili sredstvo za punjenje prisutno u količini u rasponu od 30% do 50%, po masi.
The pharmaceutical composition of claim 1 wherein the compound of formula (I) is present in an amount within the range of from 40% to 60% by weight. 
Farmaceutski sastav prema patentnom zahtjevu 1 gdje je spoj formule (I) prisutan u količini u rasponu od 40% do 60% po masi.
The pharmaceutical composition of claim 1 wherein the compound of Formula (I) is: 
Farmaceutski sastav prema patentnom zahtjevu 1 gdje je spoj Formule (I):
The pharmaceutical composition of claim 4, wherein the compound is present in an amount of 50 mg to 300 mg. 
Farmaceutski sastav prema patentnom zahtjevu 4, gdje je spoj prisutan u količini od 50 mg do 300 mg.
The pharmaceutical composition of claim 4, wherein the compound is present in an amount of 300 mg. 
Farmaceutski sastav prema patentnom zahtjevu 4, gdje je spoj prisutan u količini od 300 mg.
The pharmaceutical composition of claim 4 for use in a method for treating a sodium-dependent glucose transporter mediated disorder. 
Farmaceutski sastav prema patentnom zahtjevu 4 za primjenu u metodi liječenja poremećaja natrij-zavisnog transporta glukoze.
The pharmaceutical composition of claim 10 wherein the compound is administered at a dose of from 50 mg to 300 mg once daily. 
Farmaceutski sastav prema patentnom zahtjevu 10, gdje se spoj administrira u dozi od 50 mg do 300 mg jednom dnevno.
The pharmaceutical composition of claim 10 wherein the compound is administered at a dose of 100 mg per day. 
Farmaceutski sastav prema patentnom zahtjevu 10, gdje se spoj administrira u dozi od 100 mg dnevno.
The pharmaceutical composition of claim 10 wherein the compound is administered at a dose of 300 mg per day. 
Farmaceutski sastav prema patentnom zahtjevu 10, gdje se spoj administrira u dozi 300 mg dnevno.
1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene), or pharmaceutically acceptable salt thereof present in an amount within the range of from 40% to 60% by weight; 
1-(β-D-glukopiranozil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil] benzen), ili njegovu farmaceutski prihvatljivu sol u količini u rasponu od 40% do 60%, po masi;
a diluent or filler comprising a combination of microcrystalline cellulose and lactose present in an amount within the range of from 30% to 50% by weight; 
otapalo ili sredstvo za punjenje koje sadrži kombinaciju mikrokristala celuloze i laktoze prisutno u količini u rasponu od 30% do 50%, po masi;
at least one disintegrant in an amount within the range of from 3% to 10% by weight; 
najmanje jedno sredstvo za dezintegraciju u količini u rasponu od 3% do 10%, po masi;
at least one binder present in an amount within the range of from 0.5% to 5% by weight; and 
najmanje jedno sredstvo za vezivanje prisutno u količini u rasponu od 0.5% do 5%, po masi; i
wherein the % by weight is based on the weight of the formulation. 
gdje je maseni % zasnovan na masi formulacije.
The pharmaceutical composition of any one of claims 1 to 15, wherein the formulation is a tablet. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva od 1 do 15, gdje je formulacija u obliku tablete.
Multilayer films for naked collation of single packs of 6 or more, comprising at least a core layer, an inner layer and an outer layer wherein: 
Primjena za golu kolaciju pakiranja da se formiraju paketi od 6 ili više pakiranja, višeslojnih filmova koji sadrže najmanje središnji sloj, unutrašnji sloj i vanjski sloj gdje:
Multilayer films according to claims 1-8 wherein the core layer consists essentially of propylene and/or butene homopolymers having melting temperature in the range 140-170°C. 
Primjena u skladu sa patentnim zahtjevima 1-11 gdje središnji sloj višeslojnih filmova sadrži u suštini propilen i/ili buten homopolimere koji imaju točku topljenja u rasponu 140-170°C.
Multilayer films according to claims 1-11 comprising more than three layers wherein the inner, outer and core layer of the multilayer films are the inner, outer and core layers according to claims 1-11, the added layers being equal to or different from those of the multilayer film of claims 1-10. 
Primjena u skladu sa patentnim zahtjevima 1-13 gdje višeslojni filmovi sadrže više od tri sloja gdje unutrašnji, vanjski i središnji sloj višeslojnih filmova su unutrašnji, vanjski i središnji slojevi prema patentnim zahtjevima 1-13, dodati slojevi koji su jednaki ili različiti od onih višeslojnih filmova u patentnim zahtjevima 1-13.
supplying a film for naked collation according to claims 1-14 to wrap the single packs arranged one close to the other, 
opskrbu filma za golu kolaciju prema patentnim zahtjevima 1-14 za obavijanje pojedinačnih pakiranja koji su raspoređeni jedan blizu drugog,
wrapping the single packs arranged one close to the other in the inner layer of the naked collation multilayer film according to claims 1-14 and closing the naked collation multilayer film by sealing at temperatures in the range 60°C-80°C. 
obavijanje pojedinačnih pakiranja koji su raspoređeni jedan blizu drugog u unutrašnjem sloju višeslojnog filma gole kolacije prema patentnim zahtjevima 1-14 i zatvaranje višeslojnog filma gole kolacije zaptivanjem na temperaturama u rasponu 60°C-80°C.
A compound of formula (I): wherein A and A' independently represent a phenylene group or a pyridylene group; 
Spoj s formulom (I): [image] naznačen time da A i A' neovisno predstavljaju fenilen skupinu ili piridilen skupinu;
is a -NH-(CH2)a-N6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt. 
je skupina -NH-(CH2)a-NR6R7 ili skupina 4-metilpiperazinil, pri čemu je a cijeli broj od 1 do 4, R6 i R7 predstavljaju neovisno skupinu (C1-C4)alkil, ili R6 i R7 zajedno s atomom dušika na koji su vezani tvore heterocikličku skupinu koja je odabrana od skupine 4-metilpiperazinil, morfolino skupine, pirolidinil skupine i piperidino skupine; ili bilo koja od njegovih farmaceutski prihvatljivih soli.
A compound of formula (I) according to claim 1 wherein A and A' independently represent a phenylene group or a pyridylene group; 
Spoj s formulom (I) prema zahtjevu 1 naznačen time da A i A' neovisno predstavljaju fenilen skupinu ili piridilen skupinu;
is a -NH-(CH2)a-NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 2 to 3, R6 and R7 representing an ethyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt. 
je skupina -NH-(CH2)a-NR6R7 ili skupina 4-metilpiperazinil, pri čemu je a cijeli broj od 2 do 3, R6 i R7 predstavljaju etilnu skupinu, ili R6 i R7 zajedno s atomom dušika na koji su vezani tvore heterocikličku skupinu koja je odabrana između skupine 4-metilpiperazinil, morfolino skupine, pirolidinil skupine i piperidino skupine; ili bilo koja od njegovih farmaceutski prihvatljivih soli.
is a -NH-(CH2)a-NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 2 to 3, R6 and R7 representing an ethyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt. 
je skupina -NH-(CH2)a-NR6R7 ili skupina 4-metilpiperazinil, pri čemu je a cijeli broj od 2 do 3, R6 i R7 predstavljaju etilnu skupinu, ili R6 i R7 zajedno s atomom dušika na koji su vezani tvore heterocikličku skupina koja je odabrana između skupine 4-metilpiperazinil, morfolino skupine, pirolidinil skupine i piperidino skupine; ili bilo koja od njegovih farmaceutski prihvatljivih soli.
A compound of formula (Ic) according to claims 1, 2, 3 and 6, wherein R2 is a hydrogen atom or a methyl group; R3 is a 4-pyridyl group or a 4-pyrimidinyl group; R4 is a carbonyl group; and R5 is a -NH-(CH2)a-NR6R7 group, a being an integer 3, R6 and R7 representing an ethyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is a 4-methylpiperazinyl group; 
Spoj s formulom (Ic) prema zahtjevima 1, 2, 4 i 7, naznačen time da R2 je vodikov atom ili metilna skupina; R3 je skupina 4-piridil ili skupina 4-pirimidinil; R4 je karbonilna skupina; i R5 je skupina -NH-(CH2)a-NR6R7, a je cijeli broj 3, R6 i R7 predstavljaju etilnu skupinu, ili R6 i R7 zajedno s atomom dušika na koji su vezani tvore heterocikličku skupinu koja je skupina 4-metilpiperazinil;
or any one of its pharmaceutically acceptable salt. A compound of formula (Id) according to claims 1, 2, 3 and 8, wherein R2 is a hydrogen atom; R3 is a 4-pyridyl group; R4 is a carbonyl group; and R5 is a -NH-(CH2)a-NR6R7 group, a being an integer 3, R6 and R7 representing an ethyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is a 4-methylpiperazinyl group; 
Spoj s formulom (Id) prema zahtjevima 1, 2, 3, 4 i 8, naznačen time da R2 je vodikov atom; R3 je skupina 4-piridil; R4 je karbonilna skupina; i R5 je skupina -NH-(CH2)a-NR6R7, a je cijeli broj 3, R6 i R7 predstavljaju etilnu skupinu, ili R6 i R7 zajedno s atomom dušika na koji su vezani tvore heterocikličku skupinu koja je skupina 4-metilpiperazinil;
A compound of formula (Ie) according to claims 1, 2, 3, 4 and 10, wherein R2 is a hydrogen atom; R3 is a 4-pyridyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a -NH-(CH2)a-NR6R7 group, a being an integer 3, R6 and R7 representing an ethyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; 
Spoj s formulom (Ie) prema zahtjevima 1, 2, 3, 4 i 10, naznačen time da R2 je vodikov atom; R3 je skupina 4-piridil; R4 je karbonilna skupina ili sulfonilna skupina; i je -NH-(CH2)a-NR6R7 skupina, a je cijeli broj 3, R6 i R7 predstavljaju etilnu skupinu, ili R6 i R7 zajedno s atomom dušika na koji su vezani tvore heterocikličku skupinu koja je odabrana između skupine 4-metilpiperazinil, morfolino skupine, pirolidinil skupine i piperidino skupine;
A compound of formula (I) according to claims 1 to 13 for use as a medicine. 
Spoj s formulom (I) prema zahtjevima 1 do 13 naznačen time da je za uporabu kao lijek.
A compound of formula (I) according to claims 1 to 13 for use for preventing and/or inhibiting and/or treating cancer. 
Spoj s formulom (I) prema zahtjevima 1 do 13 naznačen time da je za uporabu za sprječavanje i/ili inhibiciju i/ili liječenje raka.
said netupitant or a pharmaceutically acceptable salt thereof is administered to said patient on day one, in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases of emesis, and which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK1 receptors in the striatum seventy-two hours after said administration; 
navedeni netupitant ili njegova farmaceutski prihvatljiva sol je prisutan/prisutna u terapeutski efikasnoj količini koja je efikasna za liječenje mučnine i povraćanja u toku akutne i odgođene faze emezisa, i koja ulazi u sustavnu cirkulaciju, prolazi kroz krvno moždanu barijeru i zauzima najmanje 70% NK1 receptora u striatumu sedamdeset i dva sata poslije navedene primjene;
A stack of mutually connected modular devices of claim 5, wherein connected adjacent ones of the generally polygonal modular devices before use are folded upon one another in a direction transverse to the plane of the modular devices. 
Skup međusobno povezanih uređaja iz zahtjeva 5, unutar kojeg se modularni uređaji međusobno povezuju prije uporabe, ali se prethodno preklapaju u smjeru dijagonalnom s ravninom modularnih uređaja.
Use of the stack of mutually connected modular devices of claim 3 or 4 for absorbing oil spilt on a water surface, comprising connecting plural ones of the stacks as a chain and disposing the chain onto a part of the water surface in a vicinity of the part of the water surface on which the oil has been spilt. 
[Umetnuti zahtjev 7 sa sljedeće stranice. Uporaba skupa međusobno povezanih modularnih uređaja iz zahtjeva 3 ili 4 za apsorpciju nafte prolivene na vodenoj površini, a što obuhvaća spajanje višestrukih sklopova u obliku lanca na dio vodene površine u blizini dijela vodene površine na kojoj je došlo do prolijevanja nafte.
The use of claim 8, wherein the oil has a drift direction, and wherein the chain is disposed transverse to the drift direction, wherein the stacks are oriented such that the individual cages are oriented such that their thickness directions extend transverse to the drift direction of the spilt oil. 
Korištenje zahtjeva 8, nafta se kreće u smjeru struje te se lanac postavlja dijagonalno na smjer strujanja, pri čemu su skupovi orijentirani tako da se pojedinačni kavezi usmjeravaju tako da se smjerovi njihovih zadebljanja šire poprečno sa smjerom kretanja prolivene nafte.
The use of claim 10, wherein each modular device has one cage face made of a grid-like sheet, the opposing cage face made of an oil-impervious sheet, such that the oil absorber is accessible to the oil from only one face, and the stack is used on a coastline surface on which no oil has yet been spilt, with the oil-impervious face down and the grid-like face up so as to protect the coastline surface from oil to be washed ashore. 
Korištenje skupa iz zahtjeva 10, unutar kojeg svaki modularni uređaj ima jednu stranu kaveza izrađenu od lima koji odbija naftu te taj apsorber nafte može upiti ulje samo s jedne strane, a skup se koristi na površini obale na kojoj još uvijek nije prolivena nafta, s time da je strana koja odbija naftu okrenuta prema dolje, a mrežasta strana prema gore kako bi se zaštitila priobalna površina od nafte koja bi mogla dospjeti do obale.
The use of one of claims 8 to 12, wherein the absorbent material and/or shape or the number of cages per stack is selected in dependence of the oil grade. 
Korištenje jednog od zahtjeva 8 do 12, pri čemu se materijal i/ili oblik materijala za apsorpciju ili broj kaveza po skup odabire ovisno o razredu nafte.
The use of claim 14, further comprising burning the modular device together with the absorbed oil so as to release thermal energy, and optionally converting a part of the thermal energy so released into electrical or mechanical energy. 
Korištenje zahtjeva 14 koji dalje obuhvaća spaljivanje modularnih uređaja, zajedno s apsorbiranom naftom kako bi došlo do oslobođenja toplinske energije te dio tako oslobođene toplinske energije moguće je pretvoriti u električnu ili mehaničku energiju.
A parenteral pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a surfactant system comprising a polysorbate and polyethylene glycol. 
Parenteralni farmaceutski pripravak, naznačen time što sadrži spoj formule (I) [image], ili njegovu farmaceutski prihvatljivu sol, te sustav surfaktanata, koji sadrži polisorbat i polietilen-glikol.
is either absent or a functional moiety; 
je bilo odsutan ili je funkcionalni ostatak;
is a leaving group; 
je izlazna skupina;
is O and Y is connected to X1 via an ω-amino aminocarbonyl cyclization spacer being part of Y; 
je O, a Y je povezan s X1 preko ω-amino-aminokarbonilne ciklizacijske razmaknice koja je dio Y;
the ring B atom of X11* in DB6 and DB7 is connected to a ring atom of ring A such that ring A and ring B in DB6 and DB7 are directly connected via a single bond; --- means that the indicated bond may be a single bond or a non-cumulated, optionally delocalized, double bond; 
atom X11* u prstenu B u DB6 i DB7 je povezan s atomom u prstenu u prstenu A, tako da su prsten A i prsten B u DB6 i DB7 izravno povezani jednostrukom vezom; --- znači da naznačena veza može biti jednostruka veza ili nekumulirana, izborno delokalizirana, dvostruka veza;